Introduction
Lower extremity peripheral artery disease (PAD) is defined as blockages in the major arteries that supply the leg (1, 2) . PAD is 1 of the 3 major systemic atherosclerotic diseases and has a prevalence similar to that of coronary heart disease and ischemic stroke. People with PAD may be asymptomatic but often experience claudication as the primary ischemic symptom that causes exertional leg muscle pain. When atherosclerotic artery blockages in the leg progress and become severe or when a clot travels to completely block a leg artery (arterial thromboembolism), unremitting ischemia at rest can occur. This presentation of PAD is defined as critical limb ischemia (CLI) and signifies an imminent risk of amputation if revascularization is not achieved. The etiology of more than 80% of amputations that occur in all developed nations, including those that occur in people with diabetes, are due to PAD and CLI (3) . The incidence of CLI will likely increase as the population ages because of the increasing prevalence of diabetes. If so, these preventable, morbid, and costly limb ischemic events will demand greater medical and revascularization resources (4) . This burden has an effect at the family, city, and state levels.
Major lower extremity amputation occurs at an estimated rate of 120 to 500 per million per year in Western countries (5) , and this rate increases with age (6) . The rate is estimated at 25% in patients with CLI (1, 2) . Ischemic amputation is still a commonly performed operation, even in hospitals that emphasize aggressive revascularization for limb salvage, and occurs more often in the United States among blacks than whites (7) . The age-adjusted annual rate of lower extremity amputation in the United States was reported to remain stable at approximately 30 per 100,000 per year from 1979 to 1989, despite an increase in the annual rate of percutaneous transluminal angioplasty and peripheral bypass surgery (8) . Hallett et al reported a decrease in the rate of major (but not minor) lower extremity amputation (from 36.7 to 19.0 per 100,000 annually from 1973 to 1992), while the rate of percutaneous and operative revascularization increased during the same period (6) . More recent data from Goodney et al suggest a decrease in major lower extremity amputation rates and lower extremity bypass surgery, with an associated increase in rates of endovascular procedures in older adults (9) . These conflicting estimates use different case ascertainment strategies, and we are not aware of any effort in North America or Europe to conduct surveillance of ischemic amputation rates.
The aim of this investigation was to create a surveillance methodology for the incidence of ischemic amputation in Minnesota and to identify potential geographic and demographic disparities in incidence. This method was also designed to permit creation of a conservative estimate of the direct costs and health economic burden associated with ischemic amputation at the state level. We hypothesized that there would be heterogeneity in ischemic amputation rates on the basis of geographic regions (eg, urban vs rural); that ischemic amputation would represent a significant cardiovascular disease burden compared with both coronary heart disease (CHD) and stroke mortality; that hospital-related charges and costs would be comparable to those for CHD and stroke; and that trends in the incidence of amputation may be evident during a 4-year surveillance period. We intended to close a knowledge gap on ischemic amputation and describe a surveillance strategy that could be modeled by other states.
Methods
We used data from a claims-based administrative data set compiled annually by the Minnesota Hospital Association, using the Uniform We identified lower limb amputations through ICD-9-CM codes. For each hospitalization record, up to 24 disease codes and 8 procedure codes are present. We first identified hospitalizations with any diabetes or cardiovascular disease code in the primary or secondary positions (ICD-9-CM 250.xx or 390.xx-459.xx), excluding patients with an injury code in the primary position (ICD-9-CM 800. xx-999.xx). We then identified lower limb ischemic amputations by ICD-9-CM procedure codes for lower extremity amputation (ICD-9-CM 84.10-84.19), excluding cases with an ICD-9-CM disease code for cancer (including malignant neoplasm of the bone, malignant neoplasm of skin, melanoma, and Kaposi's sarcoma). We further classified amputations as major (at or above the ankle) or minor (below the ankle). For comparison, we also identified CHD, stroke, and transient ischemic attack (TIA) hospitalizations by the presence of ICD-9-CM disease codes 410.xx-414.xx (CHD) and 430.xx-438.xx (stroke and TIA) in the primary position.
To estimate the total costs for each hospitalization, we adjusted total dollar charges by the hospital-specific cost-to-charge ratio at the time of patient discharge. For hospitalizations at facilities with no cost-to-charge ratio, depending on the hospital's location, we used the average rural hospital or urban hospital ratio for the state. Hospitalizations in South Dakota (n = 69) were not identified by facility, so we substituted the urban hospital cost- to-charge ratio, on the basis of known patterns of care for Minnesota residents hospitalized in that state. We applied this adjustment to estimate the total resource cost associated with inpatient care only, as it does not reflect costs associated with out-of-hospital imaging, procedures, officebased care, outpatient rehabilitation, or use of limb prostheses or chronic medications (10) (11) (12) (13) (14) (15) (16) (17) Continuous data are presented as medians (interquartile range); categorical data are presented as frequencies. Both inpatient hospitalization charges and costs are presented using medians, means, and sums. All analyses were conducted using SAS software version 9.2 (SAS Institute, Inc, Cary, North Carolina).
Results
There were 4,302 hospitalizations for lower limb amputations among Minnesotans from 2005 through 2008 (Table  1) . Of these, 1,831 (43%) were major, 2,470 (57%) were minor, and 1 was unspecified. The median patient age was 67, and major amputations were more likely to occur in older people. Most amputations took place among men and people who lived in an urban county. Of total amputations, 72% of cases were performed in people with diabetes, most of whom had a minor amputation. The number of CHD hospitalizations declined during the study period, while the number of ischemic amputations and stroke hospitalizations were steady ( Table 2 ). The median charge for ischemic amputation hospitalizations was similar to that for CHD and about twice as high as for stroke and TIA hospitalizations. The total direct inpatient hospital charges Centers for Disease Control and Prevention • www.cdc.gov/pcd/issues/2011/nov/11_0023.htm for all ischemic amputation hospitalizations approached 20% of the total charges for stroke and TIA.
The inflation-adjusted estimated median cost for ischemic amputation remained stable from 2005 through 2008, but the mean cost per hospitalization increased by 9.2% (Table  3) . Compared with 2005, the number of annual events in 2008 was 11.5% lower, and total annual inflation-adjusted inpatient hospital costs were 3.8% lower. The pattern in the intervening years was not monotonic.
Discussion
We used a representative hospital discharge data set from 2005 through 2008 to evaluate the incidence of ischemic amputation in Minnesota. These data demonstrated that most patients who underwent ischemic amputation were male and older. The age-adjusted annual incidence of ischemic amputation in Minnesota was low compared with the incidence reported elsewhere (6, 8) . Diabetes was prevalent in people who underwent ischemic amputation; 72% of the total ischemic amputation population had diabetes, and 63% of patients who had a major amputation had diabetes. Other studies have reported a prevalence of diabetes in ischemic amputees that ranges from 45% to 61% (22, 23) . Furthermore, we found that the resource allocation by hospitals and economic burden was high; people who underwent ischemic amputation had long hospital stays. Median inpatient hospitalization charges were similar to those for CHD patients and double those for stroke and TIA patients.
Though the systemic atherosclerosis disease process provides a common etiology for stroke, myocardial infarction, and PAD, and though systemic risk is elevated for people with each of these syndromes, the incidence of amputation, CHD mortality, and stroke mortality were not uniform across Minnesota. This finding likely reflects differing care standards for each condition, because reporting for each condition is likely to be similar (each outcome represents a "hard ischemic endpoint"). These data do not provide insight into distinctions in the process of care between coronary and stroke or CLI patients that may clarify these varying rates. Our results underscore -on a state-based and county-based level -the health disparity in care that affects the CLI population.
Visser et al estimated a cost of $45,200 for a major amputation in the first year, followed by an annual cost of $11,000 beyond the initial hospitalization (24) . In a more selected population of patients treated for CLI, the immediate cost directly attributed to amputation was $40,000 (1). The addition of subsequent rehabilitation is usually associated with a doubling of these costs (1). Our cost findings in a more general population provide additional information about immediate hospitalization charges associated with ischemic amputation. The Healthcare Cost and Utilization Project Nationwide Inpatient Sample of 39.5 million discharges in the United States in 2007 estimated median charges for amputation due to "circulatory system disorders" (exclusive of the upper limb and toe) of $45,900 and median hospital costs of $15,900 (25) . This value compares well with our estimates.
Minnesota is home to less than 2% of the total US population (19) , and Minnesotans experience lower rates of atherosclerotic disease and lower medical costs than the national average (26) (27) (28) . Nevertheless, our results delineate the health cost implications in the context of nationally limited health care resources. Ziegler-Graham et al estimated the prevalence of limb loss in the United States, projected these values through the year 2030, and suggested that ischemic limb loss is likely to rise with the aging population and an increase in diabetes and "dysvascular" disease (29) .
Differences in ischemic amputation rates in the literature may be due to the unique populations included in those distinct datasets, differing case identification criteria for ischemic amputation, inclusion or exclusion of minor amputations or people with diabetes, inclusion of first amputation events versus cumulative per-patient event rates, or multiple amputations in the ipsilateral limb. Only through use of a consistent methodology will patients, payers, departments of health, and other agencies be able to make state-to-state comparisons. Consistent application of a common cross-state case ascertainment strategy would foster creation of estimates of the incidence of lower limb ischemic amputation and costs, permitting future comparison of population-based treatment strategies. Although racial and ethnic disparities in amputation rates have been elucidated, disparities based on geography, sex, and health care coverage may become visible from regional data. Health disparities, once revealed, provide an opportunity to implement preventive health strategies that can reduce high ischemic amputation rates across and within states.
Despite the use of a representative hospital discharge data set, this study had several limitations. The limited avail-
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ability of clinical covariates in public data sets is acknowledged in the literature (30) . Multiple hospitalizations for amputation (of the same or different limb) cannot be identified because of the absence of unique patient identifiers. Another limitation is that inpatient hospitalization charges, and the subsequent adjustment with cost-to-charge ratios, do not optimally reflect the resources expended in managing this condition. These data do not distinguish between use of health care resources that were expended to treat the episode of CLI versus any associated illnesses that existed during the index hospitalization. Additionally, these charges only reflect resources expended during the inpatient hospitalization and do not reflect costs after discharge. Our cost estimate is conservative, as it does not reflect any ongoing disability costs associated with ischemic amputation. Furthermore, data for counties with few cases of ischemic amputation (ie, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] were reported, but the estimates are potentially unstable and should be interpreted with caution. Finally, our results were derived from a state that is known to be characterized by lower racial and ethnic diversity than the nation. Therefore, these data are not presumed to be generalizable to other states or regions. Despite these limitations, these data provide insight into the incidence and cost of ischemic amputation in Minnesota.
In conclusion, these data provide the first contemporary population-based estimate of ischemic amputation and hospitalization charges in a nonselected state-based population. Although the incidence of ischemic amputation in Minnesota is lower than has been reported from other studies, the direct inpatient hospital charges and estimated costs are high. a Costs calculated from hospital-specific cost-to-charge ratios in effect at time of patient discharge. All cost values are inflated to 2008 $US using the Consumer Price Index for inpatient hospital care.
